Investigational cell therapy to prevent rejection of a transplanted kidney
- Trial ID:
- IRB-20-7493
- Christopher Marsh, M.D.
Inclusion Criteria
Patients must:- • Be at least 18 years old
- • Be clinically indicated for a kidney transplant
- • Have identified a suitable living kidney donor between ages 18-60
- • Must qualify for kidney transplant through our Solid Organ Transplant Department
- • Meet additional criteria
Exclusion Criteria
Patients must not:- • Have a BMI >35
- • Be a biologically unrelated female donor to male recipient
- • Have had a previous transplant
Additional Info
- FREEDOM-1 is exploring the use an investigational cell therapy comprised of stem cells, which are immature cells, obtained from a living donor to prevent rejection after a kidney transplant. Patients will be randomized to receive the investigational therapy or standard anti-rejection treatment. Total study duration is expected to be about 5 years. Travel reimbursement is provided.
- Search for NCT 03995901 at www.clinicaltrials.gov for more information
Contact Info:
- Clinical Research Services
- CRSLeadership@scrippshealth.org